EntryPoint Capital’s Belite Bio BLTE Stock Holding History

EntryPoint Capital’s Portfolio BLTE Stock Details BLTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-781	Closed	-$35.7K	–	1442
2023 Q4	$35.7K	Buy	+781	New	+$30K	0.03%	862

Other funds holding BLTE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

VEA

Virtus ETF Advisers New York $215M AUM 53.68% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

EntryPoint Capital's BLTE Position: Q1 2024 in Review

EntryPoint Capital sold out of Belite Bio (BLTE) in Q1 2024, closing a stake of 781 shares — an estimated $35.7K sold.

EntryPoint Capital first reported a position in BLTE in Q4 2023 and held it in 1 quarter. The position peaked at $35.7K in Q4 2023. 11 funds tracked by Wall St. Rank hold BLTE as of Q1 2024.

EntryPoint Capital reported no remaining Belite Bio position as of Q1 2024 after selling out during the quarter.
EntryPoint Capital sold 781 Belite Bio shares in Q1 2024, an estimated $35.7K.
EntryPoint Capital first reported a position in Belite Bio in Q4 2023 and held it in 1 quarter.
EntryPoint Capital's Belite Bio position peaked at $35.7K in Q4 2023.
11 funds tracked by Wall St. Rank held Belite Bio as of Q1 2024.

Based on EntryPoint Capital's 13F filing for Q1 2024, filed 14 May 2024.